Wearable device deployment for Cardiovascular Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Massachusetts Chan Medical School, Worcester, MA
Cardiovascular Diseases+1 More
Wearable device deployment - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The Survivor mobile health (mHealth) study is testing the use of wearable devices (Fitbits) and a smartphone application in cancer survivors. The goal of the program is to increase survivor's physical activity levels. The Fitbit will be synced to the app and participants will receive messages and notifications about their activity levels. Participants will also complete surveys through the app asking how useful it is and ways to improve it. The study team will conduct qualitative interviews at the completion of the 3 months to see how participants liked the program, and ways it can be improved and make it more specific to cancer survivors. The study team will also conduct interviews with providers and clinic staff to assess their perceptions of patient digital health programs and preferences for receiving patient-generated health data.

Eligible Conditions

  • Cardiovascular Diseases
  • Malignancies

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cardiovascular Diseases

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: 1-month and 3-months post-enrollment

1-month and 3-months post-enrollment
Usability
1-month post-enrollment
1-Month Usability
3-months post-enrollment
3-Month Usability
Month 3
Changes in quality of life
Participant program acceptability
At study completion, within 3-months of enrollment
Changes in objective physical activity
Changes in self-report physical activity
At study completion; Within 3-month of last patient enrolled
Provider acceptability of wearable devices and preferences to receive data
Baseline
Feasibility of enrollment

Trial Safety

Safety Progress

1 of 3

Other trials for Cardiovascular Diseases

Trial Design

1 Treatment Group

Wearable device deployment
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Wearable device deployment · No Placebo Group · N/A

Wearable device deployment
Behavioral
Experimental Group · 1 Intervention: Wearable device deployment · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1-month and 3-months post-enrollment
Closest Location: University of Massachusetts Chan Medical School · Worcester, MA
Photo of massachusetts 1Photo of massachusetts 2Photo of massachusetts 3
2022First Recorded Clinical Trial
2 TrialsResearching Cardiovascular Diseases
1 CompletedClinical Trials

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,555 Previous Clinical Trials
46,915,149 Total Patients Enrolled
937 Trials studying Cardiovascular Diseases
33,463,915 Patients Enrolled for Cardiovascular Diseases
University of Massachusetts, WorcesterLead Sponsor
306 Previous Clinical Trials
741,089 Total Patients Enrolled
4 Trials studying Cardiovascular Diseases
1,500 Patients Enrolled for Cardiovascular Diseases
National Cancer Institute (NCI)NIH
12,930 Previous Clinical Trials
41,294,420 Total Patients Enrolled
14 Trials studying Cardiovascular Diseases
1,845,339 Patients Enrolled for Cardiovascular Diseases
Jamie M Faro, PhDPrincipal InvestigatorUniversity of Massachusetts Chan Medical School
1 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Cardiovascular Diseases
40 Patients Enrolled for Cardiovascular Diseases

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.\n
You are medically cleared to perform physical activity.
You have a smartphone.\n
You have the capacity to give informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.